Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Delivery of injectable thermo-sensitive hydrogel releasing nerve growth factor for spinal cord regeneration in rat animal model.

Alizadeh A., Moradi L., Katebi M., Ai J., Azami M., Moradveisi B.

Animal Study on Spinal Cord Injury, published in J Tissue Viability (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Tissue Viability (2020)
Country
England
Reported sample size
—
Source database
PubMed
PMID
32839065
DOI
10.1016/j.jtv.2020.06.008
Citations
24

Abstract (original English)

The main goal of this study was to explore the beneficial effect of nerve growth factor (NGF)-overexpressing of human adipose-derived mesenchymal stem cells (hADSCs) encapsulated in injectable chitosan/β-glycerophosphate/hydroxyethylcellulose (CS/β-GP/HEC) hydrogel for spinal cord regeneration. The CS/β-GP/HEC hydrogel and genetically transduced hADSCs using pseudo-lentiviruses-NGF were prepared. The mechanical properties, morphology and cytotoxicity of the hydrogel were investigated by rheometry, scanning electron microscope (SEM), and MTT assay, respectively. Rats animals were undergone spinal cord injury (SCI), then one-week post-injury, CS/β-GP/HEC hydrogel, transduced hADSCs and transduced hADSCs/CS/β-GP/HEC hydrogel injected into the site of the lesion. Animals with SCI and animals with laminectomy without SCI were considered as negative control and sham groups, respectively. Positive control group received no surgical intervention. At eight weeks post-injection, histological studies indicated a significant increase in cell proliferation, a smaller cavity in size at the SCI site as well as better locomotor functions for transduced hADSCs/CS/β-GP/HEC hydrogel group (P ≤ 0.05) compared to other experimental groups. Our results showed that CS/β-GP/HEC hydrogel in combination with transduced-hADSCs is able to successfully regenerate SCI. These results may be applicable in the

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsChitosanDisease Models, AnimalHydrogelsInjectionsNerve Growth FactorRatsSpectrophotometry, InfraredSpinal Cord Regeneration

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research